醫(yī)療特長（限400字內(nèi)）：
1. 從事普通外科專業(yè)30余年，長期致力于胃癌外科研究,，率先在國內(nèi)開展和推廣胃癌標(biāo)準D2和D2(+)淋巴結(jié)清掃,、鞘內(nèi)淋巴結(jié)清掃,進展期胃癌外科治療后5年生存率超過60%,治療效果達到國際先進水平;
2． 擅長胃腸間質(zhì)瘤(GIST)外科和綜合治療,；擅長結(jié)直腸腫瘤、結(jié)直腸息肉及息肉病,、炎癥性腸病及肛門良性疾病的診治,，對于全直腸系膜切除、低位保功能的直腸癌手術(shù),、全結(jié)腸切除術(shù),、結(jié)腸“J” 型貯袋重建直腸術(shù)等方面有深入研究和豐富經(jīng)驗。
3． 對于胰腺疾病,、腹膜后腫瘤,、食道癌、食道良性疾病等有豐富的診治經(jīng)驗,，尤其在胃或結(jié)腸代食道術(shù),、保留幽門的Whipple術(shù)、消化道重建術(shù)等方面在國內(nèi)屬于領(lǐng)先水平;
4．熟練應(yīng)用達芬奇機器人,、腹腔鏡及消化道內(nèi)鏡對胃腸道疾病進行診斷和治療,。
研究方向：
胃癌外科治療；胃癌淋巴結(jié)轉(zhuǎn)移機制和防治的研究,；胃腸間質(zhì)瘤（GIST）外科治和綜合治療及基礎(chǔ)臨床研究,；遺傳性胃腸道疾病的研究；結(jié)直腸癌的早期診斷和外科治療,；臨床營養(yǎng),；胰腺疾病的診治與基礎(chǔ)研究；快速康復(fù)外科,。
主要教育和工作經(jīng)歷：
1984.7 畢業(yè)于中山醫(yī)科大學(xué)留校工作
1996.6-1996.12 香港大學(xué)進修
2001.1-2002.12 美國Utah大學(xué) 博士后
1997.12-2003.12 中山醫(yī)科大學(xué)附屬第一醫(yī)院外科副教授,、副主任醫(yī)師
2003.12-至今 中山大學(xué)附屬第一醫(yī)院外科教授、主任醫(yī)師
2003.5-2005.8 中山大學(xué)附屬第一醫(yī)院院長辦公室副主任
2005.9-2014.4 中山大學(xué)附屬第一醫(yī)院胃腸胰?？浦魅?/p>
2005.9-至今 中山大學(xué)附屬第一醫(yī)院外科主任
2008.7-至今 中山大學(xué)胃癌診治研究中心主任
2011.8-至今 中山大學(xué)附屬第一醫(yī)院院長助理
2014.4-至今 中山大學(xué)附屬第一醫(yī)院胃腸外科中心主任
社會兼職：
1. 現(xiàn)任亞洲外科學(xué)會會員,，中華醫(yī)學(xué)會外科學(xué)分會委員，中華醫(yī)學(xué)會外科學(xué)分會胃腸外科學(xué)組副組長,，中國醫(yī)師協(xié)會外科醫(yī)師分會上消化道外科醫(yī)師委員會副主任委員兼秘書長,，中國抗癌協(xié)會胃癌專業(yè)委員會副主任委員，中國臨床腫瘤學(xué)會（CSCO）胃腸間質(zhì)瘤專家委員會副組長,，中國醫(yī)師協(xié)會第二屆醫(yī)學(xué)教育委員會委員;
2. 廣東省醫(yī)學(xué)會胃腸外科學(xué)分會主任委員,，廣東省健康管理學(xué)會胃腸病學(xué)專業(yè)委員會主任委員，廣東省醫(yī)療行業(yè)協(xié)會消化外科管理分會主任委員,，廣東省醫(yī)學(xué)會第七屆理事會理事,，廣東省抗癌協(xié)會第三屆理事會常務(wù)理事，廣東省抗癌協(xié)會胃癌專業(yè)委員會副主委，廣東省抗癌協(xié)會胰腺癌專業(yè)委員會副主任,，廣東省抗癌協(xié)會大腸癌專業(yè)委員會常委,，廣東省醫(yī)學(xué)會外科學(xué)分會第八屆委員會常委，國家和廣東省自然科學(xué)基金評委,，中華醫(yī)學(xué)科技獎評委,，廣東省科技獎評委
3.《消化腫瘤雜志》(電子版)主編、《中華胃腸外科雜志》副主編,、《中華普通外科文獻》編輯部副主任,、Annals of Surgery、Journal of Surgical Oncology,、《中華外科雜志》,、《中國實用外科雜志》、《中華普通外科雜志》等10余種雜志編委,。
論著：在Cancer Research, International Journal of Cancer, Cancer Letters, Annals Surgical Oncology等雜志發(fā)表論文350余篇,。
1. CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. Cancer Letters 2015，359（2）：335-343
2. Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients. Journal of Cancer Research and Clinical Oncology 2015,141（3）：443-452
3. Refractory left pleural effusion in an older patient: Atypical presentation of colorectal carcinoma. Oncology Letters 2015,，9（3）：1055-1058
4. Uncontrolled inflammation induced by AEG-1 promotes gastric cancer and is associated with poor prognosis, Cancer Res 2014 Oct 1;74(19):5541-52.
5. Systematic review of nasogastric or nasojejunal decompression after gastrectomy for gastric cancer. European Journal of Surgical Oncology 2014,，40（12）：1763-1770
6. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology 2014，140（9）：1537-1549
7. RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer. World Journal of Gastroenterology 2014,，20（29）：10094-10107
8. Impact of Pre-existing Type-2 Diabetes on Patient Outcomes After Radical Resection for Gastric Cancer: A Retrospective Cohort Study. Dig Dis Sci 2014 May;59(5):1017-24.
9. Efficacy and complications of polyethylene glycols for treatment of constipation in children: a meta-analysis.,，Medicine (Baltimore) 2014，93（16）：e65-e65
10.Clinicopathological features and trend changes of gastric carcinoma in Southern China. World J Gastroenterol. 2014 Apr 21;20(15)
11.Rare case of an abdominal mass: Reactive nodular fibrous pseudotumor of the stomach encroaching on multiple abdominal organs. World J Clin Cases. 2014 Apr 16;2(4):111-9.
12.Evaluation of para-aortic nodal dissection for locoregionally advanced gastric cancer with 1–3 involved para-aortic nodes. Chin Med J. 2014,127(3):435-441
13.Evaluation of Skeletonization of the Hepatoduodenal Ligament for the Lower Third Gastric Cancer by Propensity Score Analysis. Hepatogastroenterology. 2013 Oct;60(127):1789-96
14.Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol. 2013 Jun 7;19(21):3309-15.
15.High-expression of DJ-1 and Loss of PTEN Associated with Tumor Metastasis and Correlated with Poor Prognosis of Gastric Carcinoma. Int J Med Sci. 2013 Sep 24;10(12):1689-97.
16.Combined evaluation of centromere protein H and Ki-67 as prognostic biomarker for patients with gastric carcinoma. Eur J Surg Oncol. 2013 Feb;39(2):141-9
17.Fast-Track Surgery Improves Postoperative Clinical Recovery and Immunity After Elective Surgery for Colorectal Carcinoma:Randomized Controlled Clinical Trial. World Journal of Surgery. 2012; 36(8):1874-1880.
18.Risk factors for adverse outcome in low rectal cancer. WJG.2012;1(1):64-69.
19.Fast track surgery accelerates the recovery of postoperative insulin sensitivity. Chinese Medical Journal. 2012;9,125(18):3261-3265.
20.Use of absorbable hemostatic gauze with medical adhesive is effective for achieving hemostasis in presacral hemorrhage. Am J Surg. 2012 Apr;203(4):5-8.
21.High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer. Cancer Sci.2012 Jan; 103(1):73-79.
22.Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastriccancer. Int J Cancer.2012.Feb 15;130(4):787-797.
23.Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer. J Surg Oncol.2012 Sep 15;106(4):462-468.
24.Successful treatment of gallbladder mixed adenoneuroendocrine carcinoma with neo-adjuvant chemotherapy. Diagnostic Pathology. 2012,7:163.
25.Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 2012 Sep 1;106(3):304-10.
26.-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer. World Journal of Gastroenterology.2011 May 14;17(18):2315-2325.
27. Astrocyte-elevated gene-1 overexpression is associated with poor prognosis in gastric cancer. Med Oncol. 2011; 28(2): 455-462.
28.High Expression of PRL-3 can Promote Growth of Gastric Cancer and Exhibits a Poor Prognostic Impact on Patients. Ann Surg Oncol. 2009,1,16(1):208-219.
29.Effect of diabetes mellitus on prognosis of the patients with colorectal cancer undergoing resection: a cohort study with 945 patients. Chinese Medical Journal.2010;123(21):3084-3088.
30.Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China. Chinese Medical Journal. 2009,7,122(13):1486-1491.
31.Early operation for fulminant acute pancreatitis:a possible way to decrease mortality. Chinese Medical Journal. 2009,7,122(13):1492-1494.
32.Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients. J Cancer Res Clin Oncol. 2009 Aug; 135(8):1041-1046.
33.Comparison of patients by family history with gastric and non-gastric cancer. World J Gastroenterol. 2009,15(21):2644-2650.
34.Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: Its molecular mechanism was investigated using artificial microRNA interference. Int .J. ancer. 2008; 123,1439-1447 .
35.High Expression of PRL-3 can Promote Growth of Gastric Cancer and Exhibits a Poor Prognostic Impact on Patients. Ann Surg Oncol. 2009. 16(1): 208-19.
36.Spleen preservation in radical surgery for Gastric cardiac cancer. Ann Surg Oncolog, 2007; 14(4): 1312-1319
37.Is Albumin administration beneficial in early stage of postoperative hypoalbuminemia following gastrointestinal surgery?:A prospective randomized controlled trial. Am J Surg. 2008 Nov;196(5):751-5.
38.Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. Chin Med J (Engl). 2008 Nov 5;121(21):2167-71
專著：
1.主編《胃癌淋巴轉(zhuǎn)移》人民衛(wèi)生出版社 2011.4,。
2. 主編《直腸癌保肛手術(shù)》人民衛(wèi)生出版社 2009.2,。
3. 副主編《普通外科疾病臨床診斷與治療方案》科學(xué)技術(shù)文獻出版社 2012.5。
4. 副主編《胃癌外科學(xué)》人民衛(wèi)生出版社 2014.4,。
5.主譯《消化道腫瘤診斷與治療》人民衛(wèi)生出版社 2012.3,。
6.參編《胃腸外科學(xué)》、《消化腫瘤外科學(xué)》,、《胃腸外科手術(shù)學(xué)》,、《外科學(xué)》本科教材、《外科臨床手冊》等著作,。
其他主要工作成績（比如獲獎情況）：
1.“提高胃癌外科療效的臨床與基礎(chǔ)研究”分別獲得2005年度中華醫(yī)學(xué)會醫(yī)學(xué)科技進步二等獎和廣東省科技進步二等獎,；
2.“直腸癌保功能手術(shù)”獲得2006年度廣東省科技進步一等獎；
3.“進展期胃癌外科治療及應(yīng)用基礎(chǔ)研究”分獲2010年度中華醫(yī)學(xué)獎三等獎和廣東省科技二等獎,。
